HER-2/neu expression in primary and metastatic breast cancer
Open Access
- 14 February 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 113 (2), 301-306
- https://doi.org/10.1007/s10549-008-9931-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeThe New England Journal of Medicine, 2007
- Progress and new standards of care in the management of HER-2 positive breast cancerEuropean Journal of Cancer, 2007
- Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic diseaseBritish Journal of Cancer, 2005
- Impact of metastatic estrogen receptor and progesterone receptor status on survivalBreast Cancer Research and Treatment, 2005
- Monoclonal antibody therapy for breast cancer: HerceptinCancer Chemotherapy and Biological Response Modifiers Annual, 2003
- Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesAnnals of Oncology, 2002
- Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2001
- c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissuesJournal of Surgical Oncology, 2000
- Stability of HER-2/neu Expression Over Time and at Multiple Metastatic SitesJNCI Journal of the National Cancer Institute, 1993
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989